GLOBAL REACH. HUMAN TOUCH.
From our founding, Biorasi has been driven by one mission: to bring critical therapies to patients through collaboration, clarity, and commitment.
WHO WE ARE
Over more than 20 years, that philosophy has shaped who we are: a midsize, full-service CRO trusted by sponsors worldwide for our ability to unite scientific excellence, operational discipline, and genuine partnership. Under one solution.
MILESTONES THAT DEFINE US
- 200+ Trials
- 48 Countries
- 2 FDA Approvals in 2025
Behind every number is a therapy that reached people –including rare disease treatments that might not have made it without intervention.
HOW WE WORK
CONNECTED TEAMS, CLEAR DECISIONS
Our leadership stays engaged throughout the trial — making decisions alongside your team, not above it. This ensures faster answers, better alignment, and stakeholders that stay engaged from first contact to final close-out.
CULTURE OF ACCOUNTABILITY
Our people take personal ownership of every trial. That means anticipating challenges, addressing them head-on, and staying accountable to the sponsors, investigators, and patients we serve.
THERAPEUTIC FOCUS, GLOBAL PERSPECTIVE
We operate across five core therapeutic areas — Dermatology, Oncology, Neurology, Nephrology, and Cell Therapy — with teams that understand the nuances of each field. Combined with a global site network in 48 countries, we execute trials wherever patients are.
WHAT DRIVES US
At Biorasi, we believe every trial is more than a project — it’s a responsibility. The work we do impacts real lives, and that’s why we approach every partnership with focus, humility, and determination. Our values of Reliability, Flexibility, and Accessibility aren’t marketing jargon — they’re the principles we follow daily to deliver meaningful results.
FROM OUR PARTNERS
Nataliya Agafonova, MD,
Chief Medical Officer, , Longeveron Inc.
“Throughout the project, we built strong, collaborative relationships with the Biorasi team, which meant a lot to us — we spend so much time working, and that connection matters. Special thanks to Biorasi CEO Chris O’Brien for assembling such a fantastic group of experts.”